Table 2.

 Numbers (percentages) of patients with diabetes who experienced primary end points, secondary end points, and specific adverse events

Variable	Aspirin plus antioxidant (n=320)	Aspirin plus placebo (n=318)	Placebo plus antioxidant (n=320)	Placebo plus placebo (n=318)	P value (interaction*)
Primary end points:
Composite end point†	58 (18)	58 (18)	59 (18)	57 (18)	0.92
Death from coronary heart disease or stroke	23 (7)	20 (6)	19 (6)	16 (5)	0.90
Secondary end points:
Death (any cause)	56 (18)	38 (12)	59 (18)	42 (13)	0.93
Death from coronary heart disease	15 (5)	20 (6)	15 (5)	11 (4)	0.24
Stroke death	8 (3)	0 (0)	4 (1)	5 (2)	0.004
Non-fatal myocardial infarction	21 (7)	34 (11)	28 (9)	28 (9)	0.20
Non-fatal stroke	18 (6)	11 (4)	18 (6)	23 (7)	0.14
Above ankle amputation for critical limb ischaemia	6 (2)	5 (2)	4 (1)	5 (2)	0.69
Transient ischaemic attack	3 (1)	11 (4)	8 (3)	12 (4)	0.25
Coronary artery bypass surgery	4 (1)	6 (2)	8 (3)	8 (3)	0.61
Coronary artery angioplasty	3 (1)	4 (1)	4 (1)	4 (1)	0.78
Development of angina	31 (10)	39 (12)	38 (12)	40 (13)	0.59
Peripheral arterial bypass surgery	3 (1)	4 (1)	1 (0.3)	4 (1)	0.44
Peripheral arterial angioplasty	6 (2)	5 (2)	6 (2)	7 (2)	0.71
Development of critical limb ischaemia	13 (4)	8 (3)	9 (3)	10 (3)	0.37
Development of claudication	39 (12)	58 (18)	58 (18)	49 (15)	0.032
Adverse events:
Malignancy	29 (9)	24 (8)	36 (11)	32 (10)	0.85
Gastrointestinal bleeding	15 (5)	13 (4)	13 (4)	18 (6)	0.36
Gastrointestinal symptoms including dyspepsia	33 (10)	40 (13)	36 (11)	58 (18)	0.31
Arrhythmia	28 (9)	27 (9)	22 (7)	25 (8)	0.67
Allergy, including skin rash	34 (11)	38 (12)	34 (11)	30 (9)	0.47

*Test for interaction between aspirin and antioxidant.

†Death from coronary heart disease or stroke, non-fatal myocardial infarction or stroke, or above ankle amputation for critical limb ischaemia.